Literature DB >> 18216155

Epidemiology of chlamydial infection: are we losing ground?

M L Rekart1, R C Brunham.   

Abstract

Are we losing ground in our efforts to control sexually transmitted Chlamydia trachomatis infection? Before we can answer this question, we must first consider recent trends in Chlamydia from around the world to establish a baseline for understanding the possible explanations underlying these data.

Entities:  

Mesh：

Year:  2008        PMID： 18216155     DOI： 10.1136/sti.2007.027938

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN： 1368-4973            Impact factor:   3.519


  33 in total

1.  Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model.

Authors:  Chunmei Cheng; Sukumar Pal; Ilham Bettahi; Kristie L Oxford; Peter A Barry; Luis M de la Maza
Journal:  Vaccine       Date:  2011-03-04       Impact factor: 3.641

2.  PmpG303-311, a protective vaccine epitope that elicits persistent cellular immune responses in Chlamydia muridarum-immune mice.

Authors:  Raymond M Johnson; Hong Yu; Micah S Kerr; James E Slaven; Karuna P Karunakaran; Robert C Brunham
Journal:  Infect Immun       Date:  2012-03-19       Impact factor: 3.441

3.  Innate immunity is sufficient for the clearance of Chlamydia trachomatis from the female mouse genital tract.

Authors:  Gail L Sturdevant; Harlan D Caldwell
Journal:  Pathog Dis       Date:  2014-04-10       Impact factor: 3.166

4.  Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge.

Authors:  Bharat K R Chaganty; Ashlesh K Murthy; Shankar J Evani; Weidang Li; M Neal Guentzel; James P Chambers; Guangming Zhong; Bernard P Arulanandam
Journal:  Vaccine       Date:  2010-01-05       Impact factor: 3.641

5.  Evaluation design of a systematic, selective, internet-based, Chlamydia screening implementation in the Netherlands, 2008-2010: implications of first results for the analysis.

Authors:  Ingrid V F van den Broek; Christian J P A Hoebe; Jan E A M van Bergen; Elfi E H G Brouwers; Eva M de Feijter; Johannes S A Fennema; Hannelore M Götz; Rik H Koekenbier; Sander M van Ravesteijn; Eline L M Op de Coul
Journal:  BMC Infect Dis       Date:  2010-04-07       Impact factor: 3.090

6.  Current crisis or artifact of surveillance: insights into rebound chlamydia rates from dynamic modelling.

Authors:  David M Vickers; Nathaniel D Osgood
Journal:  BMC Infect Dis       Date:  2010-03-16       Impact factor: 3.090

7.  Identifying catalytic residues in CPAF, a Chlamydia-secreted protease.

Authors:  Ding Chen; Jijie Chai; P John Hart; Guangming Zhong
Journal:  Arch Biochem Biophys       Date:  2009-05-01       Impact factor: 4.013

Review 8.  Chlamydia trachomatis control requires a vaccine.

Authors:  Robert C Brunham; Rino Rappuoli
Journal:  Vaccine       Date:  2013-01-29       Impact factor: 3.641

9.  Sexually transmitted infections and risk factors for gonorrhea and chlamydia in female sex workers in Soc Trang, Vietnam.

Authors:  Thuong Vu Nguyen; Nghia Van Khuu; Truc Thanh Thi Le; Anh Phuong Nguyen; Van Cao; Dung Chi Tham; Roger Detels
Journal:  Sex Transm Dis       Date:  2008-11       Impact factor: 2.830

10.  Immunobiological outcomes of repeated chlamydial infection from two models of within-host population dynamics.

Authors:  David M Vickers; Qian Zhang; Nathaniel D Osgood
Journal:  PLoS One       Date:  2009-09-03       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.